JP2010529986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529986A5 JP2010529986A5 JP2010512211A JP2010512211A JP2010529986A5 JP 2010529986 A5 JP2010529986 A5 JP 2010529986A5 JP 2010512211 A JP2010512211 A JP 2010512211A JP 2010512211 A JP2010512211 A JP 2010512211A JP 2010529986 A5 JP2010529986 A5 JP 2010529986A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- alkyl
- halo
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93474307P | 2007-06-15 | 2007-06-15 | |
| US60/934,743 | 2007-06-15 | ||
| US7038608P | 2008-03-21 | 2008-03-21 | |
| US61/070,386 | 2008-03-21 | ||
| PCT/US2008/007458 WO2008156707A1 (en) | 2007-06-15 | 2008-06-13 | Therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014066482A Division JP6063410B2 (ja) | 2007-06-15 | 2014-03-27 | 治療化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529986A JP2010529986A (ja) | 2010-09-02 |
| JP2010529986A5 true JP2010529986A5 (OSRAM) | 2011-08-04 |
| JP5513378B2 JP5513378B2 (ja) | 2014-06-04 |
Family
ID=40156534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512211A Active JP5513378B2 (ja) | 2007-06-15 | 2008-06-13 | 治療化合物 |
| JP2014066482A Expired - Fee Related JP6063410B2 (ja) | 2007-06-15 | 2014-03-27 | 治療化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014066482A Expired - Fee Related JP6063410B2 (ja) | 2007-06-15 | 2014-03-27 | 治療化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8586634B2 (OSRAM) |
| EP (1) | EP2164324B1 (OSRAM) |
| JP (2) | JP5513378B2 (OSRAM) |
| WO (1) | WO2008156707A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0905515D0 (en) * | 2009-03-31 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling methods |
| JP5932636B2 (ja) * | 2009-05-05 | 2016-06-08 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイテッド | 治療化合物 |
| EP2611433A2 (en) | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| WO2012030939A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| KR20130138770A (ko) | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| WO2012030953A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| EP3485878A1 (en) | 2010-09-01 | 2019-05-22 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-ht2c agonists useful for weight management |
| JP2015534563A (ja) | 2012-10-09 | 2015-12-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 体重管理の方法 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN106573872B (zh) | 2014-05-19 | 2021-07-20 | 东北大学 | 5-羟色胺受体靶向化合物和方法 |
| CN107614467A (zh) * | 2015-05-19 | 2018-01-19 | 东北大学 | 用于调节外周组织中血清素受体的化合物和方法 |
| EP4370497A4 (en) * | 2021-07-14 | 2025-04-30 | Northeastern University | INVERSE AGONISTS OF SEROTONIN 5-HT2A, 5-HT2B AND 5-HT2C RECEPTORS |
| WO2023168022A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocybin |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH427780A (de) | 1962-08-30 | 1967-01-15 | Sandoz Ag | Verfahren zur Herstellung von neuen Aryl-tetralyl-Verbindungen |
| FR1480455A (fr) | 1965-05-05 | 1967-05-12 | Geigy Ag J R | Méthano-benzazocines et leur préparation |
| FR2319332A1 (fr) * | 1975-07-28 | 1977-02-25 | Roussel Uclaf | Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits |
| FR2353519A1 (fr) | 1975-12-08 | 1977-12-30 | Roussel Uclaf | Nouveaux derives de l'aminobenzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments desdits produits |
| WO1987004430A2 (en) * | 1986-01-16 | 1987-07-30 | Schering Corporation | Fused benzazepines |
| AU624854B2 (en) | 1988-07-29 | 1992-06-25 | Schering Corporation | A process for the enantiospecific synthesis of intermediates for hexahydro-benzo(d)naphtho(2,1-b)azepines |
| JPH05217455A (ja) | 1992-01-31 | 1993-08-27 | Tanaka Kikinzoku Kogyo Kk | 電気接点の製造方法 |
| US5461147A (en) | 1993-09-27 | 1995-10-24 | Schering Corporation | Process for preparing benzazepine intermediates for the synthesis of D1 antagonists |
| CA2364571A1 (en) * | 1999-03-15 | 2000-09-21 | Merck & Co., Inc. | Isoforms of mouse serotonin 5-ht2c receptor |
| US6875866B2 (en) * | 2002-02-21 | 2005-04-05 | Schering Corporation | Process for synthesis of D1 receptor antagonists |
| AU2003217654A1 (en) * | 2002-02-22 | 2003-09-09 | The Regent Of The University Of California | METHOD OF TREATMENT OF HYPERTENSION USING SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs) |
| EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
| CN1823059A (zh) | 2003-05-22 | 2006-08-23 | 先灵公司 | 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物 |
| US7115767B2 (en) * | 2003-07-18 | 2006-10-03 | Abbott Laboratories | Tetraline derivatives as ghrelin receptor modulators |
| WO2005101979A2 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| AU2006235318A1 (en) * | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
| WO2007081542A2 (en) * | 2006-01-06 | 2007-07-19 | Sepracor Inc. | Tetralone-based monoamine reuptake inhibitors |
-
2008
- 2008-06-13 US US12/452,100 patent/US8586634B2/en not_active Expired - Fee Related
- 2008-06-13 JP JP2010512211A patent/JP5513378B2/ja active Active
- 2008-06-13 WO PCT/US2008/007458 patent/WO2008156707A1/en not_active Ceased
- 2008-06-13 EP EP08779649.6A patent/EP2164324B1/en not_active Not-in-force
-
2013
- 2013-11-19 US US14/084,339 patent/US9422229B2/en not_active Expired - Fee Related
-
2014
- 2014-03-27 JP JP2014066482A patent/JP6063410B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529986A5 (OSRAM) | ||
| JP4497928B2 (ja) | α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド | |
| JP2019514882A5 (OSRAM) | ||
| JP2019514876A5 (OSRAM) | ||
| JP2008510762A5 (OSRAM) | ||
| JP2006514626A5 (OSRAM) | ||
| WO2010110231A1 (ja) | 置換された３－ヒドロキシ－４－ピリドン誘導体 | |
| JP2009525312A5 (OSRAM) | ||
| CN104302292A (zh) | 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物 | |
| JP2008543860A5 (OSRAM) | ||
| WO2013053739A1 (en) | Process for preparing factor xa inhibitors | |
| JP2011517443A5 (OSRAM) | ||
| AU2009289329A1 (en) | Triazole derivatives and their use as nicotinic acetylcholine receptor modulators | |
| JP2009538910A5 (OSRAM) | ||
| JP2014524476A5 (OSRAM) | ||
| JP2017508733A5 (OSRAM) | ||
| JP4497927B2 (ja) | 酢酸およびプロピオン酸のアミド類 | |
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| CN114805330A (zh) | Hpk1抑制剂、其制备方法、药物组合物及其应用 | |
| JP2018520188A (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 | |
| JP2012532191A5 (OSRAM) | ||
| CN105418610A (zh) | 一种10-羟基吴茱萸碱类抗肿瘤化合物及其制备方法和应用 | |
| JP2011519845A5 (OSRAM) | ||
| CN114423762A (zh) | 大环类衍生物及其制备方法和用途 | |
| JP2020507567A5 (OSRAM) |